動物向け調剤市場- 世界の産業規模、シェア、動向、機会、予測、セグメント、製品別、動物タイプ別、投与経路別、地域別、競合、2020年～2030年

動物向け調剤の世界市場規模は2024年に16億3,000万米ドルで、予測期間には26億1,000万米ドルに達すると予測され、2030年までのCAGRは8.14%です。

世界動物向け調剤市場は、ペットの飼育が増加し続け、個別化された獣医学的ケアの必要性が高まるにつれて、大きな成長を遂げています。調剤薬局は、特に市販薬が入手できなかったり、有効でない場合に、動物特有のニーズに合わせてカスタマイズされた薬を提供します。この市場を牽引しているのは、ペットの飼い主や獣医師の間で、配合薬の利点に対する認識が高まっていることです。ペットも人間と同様、個別の治療が必要な特定の健康状態を持っているため、カスタマイズされたソリューションに対する需要が急増しています。これらの医薬品は、標準化された治療では不十分なことが多い慢性疾患、アレルギー、希少疾患の管理には特に重要です。ペットのヘルスケアに対する飼い主の投資意欲の高まりがこの需要をさらに押し上げ、動物向け調剤サービスの市場を拡大しています。

市場の主な動向には、より効果的で正確な処方を可能にする動物用配合技術の進歩が含まれます。ドラッグデリバリーシステムの改良や新規賦形剤の使用などの技術革新により、配合薬の品質が向上しています。獣医の専門家は、さまざまな動物の病気に対してより良い治療法を提供するために、ますますこれらの高度な製剤に頼るようになっています。さらに、獣医診療がより個別化された治療へとシフトするにつれ、コンパニオンアニマルと家畜の両方に対する配合薬の需要が顕著に増加しています。この動向は、規制遵守への関心の高まりと相まって、配合薬が要求される安全性と有効性の基準を満たしていることを保証しています。このような技術開発は、今後数年間の市場成長をさらに促進すると予想されます。

有望な成長にもかかわらず、市場はその軌道に影響を与えかねないいくつかの課題に直面しています。主な懸念事項の1つは、動物向け調剤を取り巻く規制やガイドラインが統一されていないことです。動物用調剤薬局は規制基準の対象となっているが、世界共通のガイドラインがないため、地域間で一貫した品質と安全性を確保することが難しいです。このような規制のばらつきは市場の分断を招き、サプライチェーンを複雑化し、地域によっては配合薬へのアクセスを制限することになります。さらに、臨床データが限られているため、配合薬の長期的な安全性と有効性に懸念があり、一部の獣医専門家の間で躊躇が生じる可能性があります。こうした規制の矛盾に対処し、配合薬の臨床エビデンスを強化することは、市場の成長を維持し、業界に対する消費者の信頼を維持する上で極めて重要です。

主な市場促進要因

ペットの飼育増加と動物の健康に対する意識の高まり

配合技術の進歩

動物の慢性疾患の増加

主な市場課題

限られた認識と教育

臨床データと調査の不足

主な市場動向

個別化された動物用医薬品に対する需要の増加

動物用調剤薬局の成長

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の動物向け調剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（抗感染剤、抗炎症剤、ホルモンおよび代替物、中枢神経系薬剤、その他）
  • 動物タイプ別（ペット、家畜）
  • 投与経路別（経口、注射、局所、その他）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米の動物向け調剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 動物タイプ別
  • 投与経路別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の動物向け調剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 動物タイプ別
  • 投与経路別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の動物向け調剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 動物タイプ別
  • 投与経路別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の動物向け調剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 動物タイプ別
  • 投与経路別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの動物向け調剤市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別
  • 動物タイプ別
  • 投与経路別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併および買収（該当する場合）
• 製品の発売（該当する場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Wedgewood Village Pharmacy, LLC
• Vimian Group AB
• Pharmaca Health Intelligence Ltd
• Akina Animal Health
• Triangle Compounding Pharmacy
• Davis Islands Pharmacy & Compounding Lab
• Custom Med Compounding Pharmacy
• Central Compounding Center South
• Wellness Compounding Pharmacy of Cary
• Millers Pharmacy

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Animal Drug Compounding Market was valued at USD 1.63 Billion in 2024 and is expected to reach USD 2.61 Billion in the forecast period with a CAGR of 8.14% through 2030. The Global Animal Drug Compounding Market is experiencing significant growth as pet ownership continues to rise and the need for personalized veterinary care increases. Compounding pharmacies offer customized medication tailored to the unique needs of animals, especially when commercial drugs are not available or effective. This market is being driven by the growing recognition among pet owners and veterinarians of the benefits of compounded drugs. Pets, like humans, have specific health conditions that may require individualized treatment, prompting a surge in demand for customized solutions. These medications are particularly important for managing chronic conditions, allergies, or rare diseases, where standardized treatments often fall short. The increasing willingness of pet owners to invest in their pets' healthcare is further boosting this demand, expanding the market for animal drug compounding services.

Key trends in the market include the ongoing advancements in veterinary compounding technologies, which enable the creation of more effective and precise formulations. Technological innovations, such as improved drug delivery systems and the use of novel excipients, are enhancing the quality of compounded medications. Veterinary professionals are increasingly relying on these advanced formulations to provide better treatment options for a range of animal diseases. Moreover, as veterinary practices shift towards more individualized care, there is a noticeable rise in the demand for compounded drugs for both companion animals and livestock. This trend is coupled with an increased focus on regulatory compliance, ensuring that compounded medications meet the required safety and efficacy standards. These technological developments are anticipated to further fuel the market growth in the coming years.

Despite the promising growth, the market faces several challenges that could impact its trajectory. One of the primary concerns is the lack of uniformity in regulations and guidelines surrounding animal drug compounding. While veterinary compounding pharmacies are subject to regulatory standards, the absence of universal global guidelines makes it difficult to ensure consistent quality and safety across regions. This variation in regulations can lead to market fragmentation, complicating the supply chain and limiting access to compounded drugs in some areas. Furthermore, there are concerns regarding the long-term safety and efficacy of compounded drugs due to limited clinical data, which may create hesitation among some veterinary professionals. Addressing these regulatory inconsistencies and building stronger clinical evidence for compounded medications will be crucial for sustaining market growth and maintaining consumer trust in the industry.

Key Market Drivers

Growing Pet Ownership and Awareness of Animal Health

The Global Animal Drug Compounding Market is experiencing significant growth, driven by the increasing pet ownership and heightened awareness of animal health. As of 2024, approximately 66% of U.S. households, equating to 86.9 million homes, own a pet, marking a substantial rise from 56% in 1988. This upward trend in pet ownership is mirrored globally, with millions of households embracing pets as integral family members.

Concurrently, there is a growing recognition among pet owners of the importance of comprehensive healthcare for their animals. This awareness has led to increased spending on pet health, including veterinary services, medications, and preventive care. In the United States alone, pet owners spent USD 89 billion on their pets in 2023, reflecting a 16% increase in pet food sales compared to previous years. This surge in expenditure underscores the prioritization of pet health and wellness.

The combination of rising pet ownership and enhanced health consciousness among owners has spurred demand for personalized veterinary care. Compounded medications offer tailored solutions for various animal health conditions, addressing specific needs that standard pharmaceuticals may not meet. This is particularly evident in the growing market for pet health products and services.

Advancements in Compounding Technology

Advancements in compounding technology are significantly driving the Global Animal Drug Compounding Market. The evolution of compounding practices has enabled the creation of customized medications tailored to the specific needs of individual animals, addressing conditions where standard pharmaceuticals may not be effective. This customization is particularly beneficial for managing chronic diseases, allergies, and other health issues prevalent in pets.

The U.S. Food and Drug Administration (FDA) has recognized the importance of compounding in veterinary medicine and has established guidelines to ensure the safety and efficacy of compounded animal drugs. In April 2022, the FDA issued final Guidance for Industry (GFI) #256, titled "Compounding Animal Drugs from Bulk Drug Substances," to help protect animal health by balancing the need for access to compounded drugs with the necessity of ensuring their safety and effectiveness.

The FDA's Veterinary Innovation Program (VIP), launched in October 2018, further supports the development of innovative veterinary products, including compounded medications. The program aims to provide greater certainty in the regulatory process, encourage development and research, and support an efficient and predictable regulatory approach for emerging veterinary products. These regulatory advancements have facilitated the integration of new technologies into veterinary compounding practices. Emerging technologies, such as animal cells, tissues, and cell- and tissue-based products (ACTPs), offer potential novel therapies for various veterinary medical needs, including musculoskeletal diseases and inflammatory conditions. The FDA is committed to using a science- and risk-based approach to regulate products of emerging technologies, ensuring consumer confidence and fostering the development of products that improve animal health.

Increasing Incidence of Chronic Diseases in Animals

The increasing incidence of chronic diseases in animals significantly drives the Global Animal Drug Compounding Market. As pets live longer due to advancements in veterinary care and improved nutrition, they become more susceptible to chronic conditions such as arthritis, diabetes, and kidney disease. For instance, chronic kidney disease (CKD) is prevalent among cats, with studies indicating that approximately 30% of cats over the age of 15 are affected.

This rise in chronic conditions has led to an increased demand for personalized and effective treatment options. Compounded medications offer tailored solutions that address specific health needs, providing veterinarians with the flexibility to adjust dosages and formulations to suit individual animals. Such customization is particularly beneficial for managing chronic diseases, where standard medications may not be effective or suitable.

The growing prevalence of chronic diseases in animals underscores the need for specialized treatments, thereby driving the demand for compounded medications. As pet owners become more aware of these health issues and seek effective management strategies, the market for animal drug compounding continues to expand, offering opportunities for innovation and growth in veterinary pharmaceutical services.

Key Market Challenges

Limited Awareness and Education

Limited awareness and education represent significant challenges for the Global Animal Drug Compounding Market. The lack of comprehensive knowledge regarding compounded medications among veterinarians and pet owners is a primary concern. Many veterinary professionals may not be fully aware of the potential benefits of compounded medications in managing complex animal health issues. This gap in awareness limits the widespread adoption of compounded drugs, particularly in regions where traditional pharmaceutical solutions are more commonly used. In addition to the professional knowledge gap, pet owners often lack understanding of the availability and effectiveness of compounded medications. This is compounded by the limited visibility of compounded drugs in mainstream veterinary practices and pharmacies. Without clear communication and education about how compounded medications can offer tailored solutions to treat specific health conditions in animals, pet owners may be hesitant to consider them as a viable option.

Veterinary schools and training programs are increasingly integrating pharmaceutical compounding into their curriculums. However, there is still a need for greater focus on educating the next generation of veterinarians about the benefits of compounding. Without proper education, many veterinarians may not feel confident in recommending compounded solutions, leaving compounded medications underutilized in veterinary care.

The lack of awareness extends to regulatory bodies, which have not consistently promoted the benefits and safety of compounded medications. Efforts from organizations such as the U.S. Food and Drug Administration (FDA) and other regulatory bodies to educate both veterinarians and pet owners on compounding guidelines and standards are still in the early stages, which hinders wider adoption.

Lack of Clinical Data and Research

Lack of clinical data and research poses a significant challenge for the Global Animal Drug Compounding Market. Despite the growing demand for personalized veterinary care, compounded medications often face scrutiny due to the limited availability of robust clinical studies supporting their safety and efficacy. Many compounded medications are formulated based on veterinary professionals' expertise rather than extensive clinical trials, leading to uncertainties about their long-term effects and optimal usage.

Compounding pharmacies typically rely on established pharmacological knowledge and guidelines, but the absence of peer-reviewed studies leaves a gap in evidence that veterinarians and pet owners can use to assess the risks and benefits of these treatments. The lack of large-scale, well-controlled studies in the veterinary compounding sector means that many veterinarians are hesitant to embrace compounded medications, especially when alternative treatments with more established clinical backing are available.

Regulatory bodies such as the U.S. Food and Drug Administration (FDA) have set guidelines for compounding animal medications, but these guidelines often lack the comprehensive clinical data that would reassure practitioners about the safety and efficacy of compounded treatments. The limited research also makes it challenging to address concerns related to the consistency and quality of compounded medications across different compounding pharmacies. The scarcity of clinical trials in veterinary compounding hampers the ability to standardize dosing, formulation, and treatment protocols, contributing to a lack of confidence in compounded drugs among veterinarians. Without more clinical data, veterinarians may opt for conventional treatments with a more established evidence base, further hindering the growth of the animal drug compounding market. Enhanced research and clinical trials are needed to build credibility and foster wider adoption of compounded medications in veterinary care.

Key Market Trends

Increased Demand for Personalized Veterinary Medicine

The increased demand for personalized veterinary medicine is a prominent trend driving the Global Animal Drug Compounding Market. As pet owners increasingly view their animals as family members, there is a growing desire for customized healthcare solutions that cater to the specific needs of individual animals. This shift towards personalized care has led to an upsurge in the use of compounded medications, which offer tailored treatments for various conditions, including chronic diseases, allergies, and age-related ailments.

Compounded drugs allow veterinarians to modify the strength, dosage, and form of medications to suit the unique needs of different animals, including companion pets, exotic animals, and livestock. Such flexibility is essential in treating conditions that may not respond well to commercially available medications. The ability to create customized formulations, such as flavored oral suspensions for finicky pets or specific dosages for small animals, increases treatment adherence and enhances the overall effectiveness of care.

As the awareness of animal health issues grows, veterinarians are recognizing the benefits of personalized medicine. Pet owners increasingly seek medications that cater to their pet's unique health conditions, leading to a higher demand for compounded solutions. The ability to address specific needs, such as hypoallergenic formulas or medications tailored for animals with multiple health conditions, is a driving force behind the demand for personalized veterinary care.

This trend aligns with the broader healthcare sector's movement toward precision medicine, where treatments are tailored to an individual's unique genetic makeup, environment, and lifestyle. In veterinary medicine, this approach provides significant improvements in the quality of care and outcomes. As pet owners become more knowledgeable and engaged in their pets' health, the demand for personalized veterinary medicine, supported by compounded drugs, is expected to continue growing, driving the market forward.

Growth of Veterinary Compounding Pharmacies

The growth of veterinary compounding pharmacies is a key trend influencing the Global Animal Drug Compounding Market. These pharmacies specialize in preparing customized medications that are tailored to the specific needs of animals, offering solutions that cannot be met by commercially available pharmaceutical products. As pet ownership continues to rise globally, there is an increasing demand for specialized and personalized care, propelling the expansion of veterinary compounding pharmacies.

The ability of these pharmacies to create individualized treatments is particularly important for managing conditions that require specialized formulations, such as chronic illnesses, behavioral disorders, or drug allergies in pets. Many animals, especially those with unique health needs, may not respond to mass-produced drugs, which makes compounded medications a crucial alternative. Veterinary compounding pharmacies are equipped to provide customized medications in various forms, including oral suspensions, transdermal gels, and injectable solutions, to meet the diverse needs of animals.

The regulatory landscape for veterinary compounding has also evolved, allowing compounding pharmacies to operate under clearer guidelines. These regulatory advancements ensure the safety and quality of compounded medications, which, in turn, boosts consumer and veterinary confidence. As a result, the growth of veterinary compounding pharmacies is expected to continue, driven by the rising demand for personalized treatments and the need for specialized care in veterinary medicine.

Segmental Insights

Product Insights

Based on the Product, CNS Agents emerged as the dominant segment in the Global Animal Drug Compounding Market in 2024. This is driven by the increasing prevalence of neurological disorders in companion animals. Pets, particularly dogs and cats, are susceptible to a variety of neurological conditions such as epilepsy, anxiety, and degenerative diseases, which require specialized treatment. Compounded CNS medications allow veterinarians to create tailored solutions that address the specific needs of animals, including adjusting dosages and formulations to improve efficacy and minimize side effects.

The rising awareness among pet owners about the importance of managing behavioral and neurological disorders in pets has significantly contributed to the demand for CNS agents. Furthermore, many off-the-shelf medications are not suitable or effective for certain animal species or conditions, driving the need for customized compounded formulations. These medications are often more palatable, available in easier-to-administer forms, and can be tailored to suit an individual animal's specific health needs. Veterinary practices are increasingly recognizing the benefits of compounded CNS medications, which has further strengthened the growth of this segment. As the veterinary care industry continues to advance and the focus on holistic, personalized treatments increases, CNS agents are expected to remain a dominant product category in the animal drug compounding market.

Route of Administration Insights

Based on the Route of Administration, Oral emerged as the dominant segment in the Global Animal Drug Compounding Market in 2024. This dominance is primarily due to its ease of use and effectiveness in delivering medications to a wide range of animal species. Oral medications are often the most convenient and cost-effective option for both veterinarians and pet owners, especially when it comes to long-term treatment for chronic conditions. This route of administration allows for precise dosage control and is suitable for a variety of compounded formulations, such as flavored tablets, liquids, or capsules, making it easier to administer to animals, particularly pets, who may be difficult to treat with injections or topical medications.

The high demand for oral medications can also be attributed to the growing focus on improving animal compliance with treatments. Many animals, especially companion animals, are more likely to accept oral medications when they are formulated in palatable flavors, reducing the stress for both the pet and the owner. Oral administration is also advantageous for managing common conditions such as infections, gastrointestinal issues, and behavioral disorders, which are frequently treated with compounded drugs. As the veterinary market continues to prioritize convenience and compliance, oral administration is expected to maintain its dominance in the animal drug compounding market.

Regional Insights

North America emerged as the dominant region in the Global Animal Drug Compounding Market in 2024. This is primarily driven by several key factors. The region has a highly developed veterinary healthcare system, with a large number of veterinary clinics and compounding pharmacies offering specialized services. The growing awareness among pet owners about the benefits of personalized treatments for animals is fueling demand for compounded medications, particularly for companion animals. The increase in pet ownership and the rising focus on pet health and wellness have led to higher expenditure on veterinary care, further boosting the market for compounded drugs.

Additionally, North America has witnessed significant advancements in compounding technologies, enabling the production of more precise and effective medications tailored to the needs of different animal species. The regulatory environment in the region is also well-established, with clear guidelines for the preparation and distribution of compounded medications, ensuring the safety and efficacy of these drugs. The increasing prevalence of chronic diseases in pets, such as arthritis, diabetes, and anxiety, has driven the demand for long-term, customized treatments that are often provided through compounded medications. As a result, North America remains a key market for animal drug compounding, with continued growth expected in the coming years.

Key Market Players

• Wedgewood Village Pharmacy, LLC
• Vimian Group AB
• Pharmaca Health Intelligence Ltd
• Akina Animal Health
• Triangle Compounding Pharmacy
• Davis Islands Pharmacy & Compounding Lab
• Custom Med Compounding Pharmacy
• Central Compounding Center South
• Wellness Compounding Pharmacy of Cary
• Millers Pharmacy

Report Scope:

In this report, the Global Animal Drug Compounding Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Animal Drug Compounding Market, By Product:

• Anti-infective Agents
• Anti-inflammatory Agents
• Hormones & Substitutes
• CNS Agents
• Others

Animal Drug Compounding Market, By Animal Type:

• Companion Animal
• Livestock Animal

Animal Drug Compounding Market, By Route of Administration:

• Oral
• Injectable
• Topical
• Others

Animal Drug Compounding Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Animal Drug Compounding Market.

Available Customizations:

Global Animal Drug Compounding Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Animal Drug Compounding Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Anti-infective Agents, Anti-inflammatory Agents, Hormones & Substitutes, CNS Agents, Others)
  • 5.2.2. By Animal Type (Companion Animal, Livestock Animal)
  • 5.2.3. By Route of Administration (Oral, Injectable, Topical, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Animal Drug Compounding Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Animal Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Animal Drug Compounding Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Animal Type
      • 6.3.1.2.3. By Route of Administration
  • 6.3.2. Mexico Animal Drug Compounding Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Animal Type
      • 6.3.2.2.3. By Route of Administration
  • 6.3.3. Canada Animal Drug Compounding Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Animal Type
      • 6.3.3.2.3. By Route of Administration

7. Europe Animal Drug Compounding Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Animal Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Animal Drug Compounding Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Animal Type
      • 7.3.1.2.3. By Route of Administration
  • 7.3.2. Germany Animal Drug Compounding Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Animal Type
      • 7.3.2.2.3. By Route of Administration
  • 7.3.3. United Kingdom Animal Drug Compounding Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Animal Type
      • 7.3.3.2.3. By Route of Administration
  • 7.3.4. Italy Animal Drug Compounding Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Animal Type
      • 7.3.4.2.3. By Route of Administration
  • 7.3.5. Spain Animal Drug Compounding Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Animal Type
      • 7.3.5.2.3. By Route of Administration

8. Asia-Pacific Animal Drug Compounding Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Animal Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Animal Drug Compounding Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Animal Type
      • 8.3.1.2.3. By Route of Administration
  • 8.3.2. India Animal Drug Compounding Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Animal Type
      • 8.3.2.2.3. By Route of Administration
  • 8.3.3. South Korea Animal Drug Compounding Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Animal Type
      • 8.3.3.2.3. By Route of Administration
  • 8.3.4. Japan Animal Drug Compounding Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Animal Type
      • 8.3.4.2.3. By Route of Administration
  • 8.3.5. Australia Animal Drug Compounding Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Animal Type
      • 8.3.5.2.3. By Route of Administration

9. South America Animal Drug Compounding Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Animal Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Animal Drug Compounding Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Animal Type
      • 9.3.1.2.3. By Route of Administration
  • 9.3.2. Argentina Animal Drug Compounding Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Animal Type
      • 9.3.2.2.3. By Route of Administration
  • 9.3.3. Colombia Animal Drug Compounding Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Animal Type
      • 9.3.3.2.3. By Route of Administration

10. Middle East and Africa Animal Drug Compounding Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Animal Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Animal Drug Compounding Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Animal Type
      • 10.3.1.2.3. By Route of Administration
  • 10.3.2. Saudi Arabia Animal Drug Compounding Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Animal Type
      • 10.3.2.2.3. By Route of Administration
  • 10.3.3. UAE Animal Drug Compounding Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Animal Type
      • 10.3.3.2.3. By Route of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Wedgewood Village Pharmacy, LLC
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Vimian Group AB
• 14.3. Pharmaca Health Intelligence Ltd
• 14.4. Akina Animal Health
• 14.5. Triangle Compounding Pharmacy
• 14.6. Davis Islands Pharmacy & Compounding Lab
• 14.7. Custom Med Compounding Pharmacy
• 14.8. Central Compounding Center South
• 14.9. Wellness Compounding Pharmacy of Cary
• 14.10. Millers Pharmacy

15. Strategic Recommendations

16. About Us & Disclaimer